Vaxine

Vaxine, established in 2002, is an Australian biotechnology company focused on developing innovative vaccine technologies, with its lead product being the Advax delta inulin adjuvant. Supported by funding contracts from the U.S. National Institutes of Health, Vaxine has developed a range of vaccines that utilize its Advax adjuvant technology to enhance immunogenicity and protection. Vaxine's human vaccine candidates include vaccines for seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile virus, malaria, rabies, and allergies. Vaxine also has a veterinary division that is commercializing vaccine adjuvants tailored to specific animal health issues.